C12N 2770/32343
Viral genome or elements thereof as genetic vector
Official title: viral genome or elements thereof as genetic vector
C12N2770/32343 (Viral genome or elements thereof as genetic vector) appears on 13 US grants and 20 published applications in this corpus.
Search patents in C12N- Granted patents
- 13
- Published applications
- 20
- Assignees
- 22
- Inventors
- 55
- Latest grant
- 23 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 1 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 1 | 1 |
| 2019 | 0 | 2 |
| 2020 | 1 | 3 |
| 2021 | 0 | 1 |
| 2022 | 1 | 3 |
| 2023 | 2 | 2 |
| 2024 | 0 | 3 |
| 2025 | 2 | 3 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Constructs and methods for preparing circular RNA23 Jun 2026US 12,662,671 B2Peking University
- Antitumor virus30 Dec 2025US 12,508,291 B2Shanxi Academy of Advanced Research and Innovation
- Pharmaceutical composition containing stabilized nucleic acid adjuvant11 Nov 2025US 12,465,644 B2Sml Biopharm Co., Ltd.
- Virus for treatment of tumor24 Oct 2023US 11,793,844 B2Xiamen University
- Recombinant polypeptides derived from FBP1 and FBP2 and uses of the same25 Apr 2023US 11,634,464 B2Chang Gung University
- Genetically modified enterovirus vectors with enhanced genomic stability2 Oct 2025US 2025/0304999 A1Virogin Biotech Canada Ltd
- Using infectious nucleic acid to treat cancer7 Aug 2025US 2025/0249053 A1Mayo Foundation for Medical Education and Research
- Parasporin expression vector and pharmaceutical composition10 Jul 2025US 2025/0223322 A1N.P.T. S.R.L.
- Modified piv5 vaccine vectors: methods of making and uses29 Aug 2024US 2024/0287544 A1Cyanvac LLC
- Mir-375- and mir-1-regulated coxsackievirus b3 has no pancreas and heart toxicity but strong antitumor efficiency in colorectal carcinomas1 Aug 2024US 2024/0252564 A1Technische UniversitäT Berlin
Most cited
By later US patents
- Coxsackie virus as a vector for delivery of anti-inflammatory cytokines16US 6,071,742 ABoard of Regents of the University of Nebraska · 2000
- Coxsackie virus vectors for delivery of nucleic acids encoding antigenic or therapeutic products6US 6,323,024 B1Board of Regents of the University of Nebraska · 2001
- Gene-modified coxsackievirus1US 10,076,547 B2Kyushu University, National University Corporation · 2018